Open Label Immunotherapy of Endometriosis

Endometriosis Clinical Trial

Official title:

Open Label, One-arm, 2-month Study of Once-daily Tablet of V-Endo as Immunotherapy of Endometriosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03340324
• Other study ID #: V-Endo
• Status: Recruiting
• Phase: Phase 2
• Start date: October 1, 2017
• Est. completion date: December 1, 2019

Study information

• Verified date: April 2019
• Source: Immunitor LLC
• Contact: Aldar Bourinbaiar, MD/PhD
• Phone: +976 95130306
• Email: aldar[@]immunitor.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Endometriosis is a chronic gynecological disease characterized by sustained painful symptoms that are responsible for a decline in the quality of life of sufferers. Endometriosis is fairly common, affecting an estimated 10%-15% of women and girls, usually during their reproductive years. Based on these rough estimates, the latest epidemiological studies suggest that over 200 million women are might be affected who may commonly have infertility problems. Additionally, endometriosis is a major factor increasing by 33-66% risk of ovarian cancer. V-Endo is a tableted preparation derived from hydrolyzed, heat-inactivated, pooled blood of women with endometriosis. When taken orally it is postulated to cause the immune tolerance and anti-inflammatory effect as a result.

Description:

Anatomically endometriosis is characterized by the presence of endometrial-type mucosa outside the uterine cavity. This tissue proliferates and causes chronic inflammation resulting in pain and excessive menstrual bleeding. Conventional treatment includes surgical and pharmacological therapy aiming at reducing painful symptoms. However, there is an unmet need in finding optimally safe and effective treatment. This study aimed to evaluate the effect of V-Endo on pain levels in women with endometriosis, focusing on reducing inflammation by immunotherapeutic intervention.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 1, 2019
• Est. primary completion date: December 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• age between 18 and 50 years

• pain visual analog scale (VAS) score over 4 (visual linear scale from 0 to 10)

• confirmation of endometriosis by laparoscopy

• no drugs used at least for one month prior to enrollment, i.e., estro-progestinic, progestinic, gonadotropin-releasing hormone (GnRH) agonists and antagonists as well as nonsteroidal anti-inflammatory drugs (NSAIDs)

Exclusion Criteria:

• presence of other associated diseases such as malignancies

• concomitant use of hormonal drugs

• menopause

• pregnancy

• surgery for endometriosis within the last month prior to study entry

• unable or unwilling to give written consent patients

• adverse reaction or hypersensitivity to active substance or excipients of V-Endo

Related Conditions & MeSH terms

• Endometriosis

Intervention

Biological:
• V-Endo
V-Endo is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood from women with endometriosis

Locations

Country	Name	City	State
Mongolia	Immunitor LLC	Ulaanbaatar

Sponsors (2)

Lead Sponsor	Collaborator
Immunitor LLC	Ekomed LLC

Country where clinical trial is conducted

Mongolia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect on pelvic pain by visual analogue scale (VAS)	The pain VAS is a continuous scale comprised of a horizontal or vertical line, usually 10 centimeters (100 mm) in length. For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 10).	2 months
Secondary	Effect of V-Endo on complete blood count (CBC)	The effect of V-Endo on complete blood cell count and clinical biochemistry will be evaluated by routine lab tests to determine whether they are within normal ranges are as described in http://onlinelibrary.wiley.com/doi/10.1002/9781118704783.app3/pdf	2 months
Secondary	Changes induced By V-Endo on life quality	Changes in life quality occurring as a result of intervention as measured by EHP-30 instrument https://innovation.ox.ac.uk/outcome-measures/endometriosis-health-profile-ehp/	2 months
Secondary	Effect of V-Endo liver and kidney biochemistry parameters	The influence on kidney and liver biochemistry parameters measured as described in http://onlinelibrary.wiley.com/doi/10.1002/9781118704783.app3/pdf	2 months